
Opinion|Videos|May 2, 2025
Evaluating Pemetrexed Exposure in FLAURA2: Key Findings and Treatment Implications
Panelists discuss how the FLAURA2 pemetrexed exposure subanalysis showed that patients could benefit from the regimen even if they didn't complete the full maintenance period as prescribed in the trial.
Advertisement
FLORA-2 Outcomes Based on Pemetrexed Exposure
Main Discussion Topics:
- Analysis of FLAURA2 outcomes based on duration of pemetrexed exposure
- Implications for real-world implementation of the regimen
- Factors influencing decisions about continuing vs discontinuing pemetrexed
Key Points for Physicians:
- Median exposure to platinum-based chemotherapy was 3 months; pemetrexed was 8.3 months; osimertinib was 22 months
- Similar progression-free survival was observed between patients receiving 3 to 9 months and 9 to 18 months of pemetrexed
- Decisions to discontinue pemetrexed are typically driven by toxicity or patient preference rather than efficacy concerns
Notable Insights:
Patients who received at least some pemetrexed maintenance beyond the initial combination phase appeared to derive the benefit of the regimen, suggesting flexibility in maintenance duration.
Clinical Significance:
Real-world implementation of FLAURA2 can incorporate individualized approaches to maintenance therapy duration while preserving efficacy benefits.
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


